1807530-05-7

Basic information

• Product Name: Hydroxy-PEG5-t-butyl acetate
• Synonyms: Hydroxy-PEG5-t-butyl acetate;OH-PEG5-CH2COOtBu;tert-butyl 17-hydroxy-3,6,9,12,15-pentaoxaheptadecanoate;[2-(2-{2-[2-(2-Hydroxyethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-acetic acid tert-butyl ester
• CAS NO: 1807530-05-7
• Molecular Formula: C16H32O8
• Molecular Weight: 352.42048
• Mol File: 1807530-05-7.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 432.4±40.0 °C(Predicted)
• Appearance: /
• Density: 1.082±0.06 g/cm3(Predicted)
• Solubility: Soluble in Water, DMSO, DCM, DMF
• PKA: 14.36±0.10(Predicted)
• CAS DataBase Reference: Hydroxy-PEG5-t-butyl acetate(CAS DataBase Reference)
• NIST Chemistry Reference: Hydroxy-PEG5-t-butyl acetate(1807530-05-7)
• EPA Substance Registry System: Hydroxy-PEG5-t-butyl acetate(1807530-05-7)

Safety Data

• Hazardous Substances Data: 1807530-05-7(Hazardous Substances Data)

Usage

Description

Hydroxy-PEG5-CH2CO2tBu is a PEG linker containing a hydroxyl group with a t-butyl protected carboxyl group. The hydrophilic PEG spacer increases solubility in aqueous media. The hydroxyl group enables further derivatization or replacement with other reactive functional groups. The t-butyl protected carboxyl group can be deprotected under acidic conditions.

Upstream product

• 4792-15-8 Pentaethylene glycol 
• 1807537-31-0 tert-butyl 1-phenyl-2,5,8,11,14,17-hexaoxanonadecan-19-oate 
• 57671-28-0 2-(2-{2-[2-(2-benzyloxyethoxy)ethoxy]ethoxy}ethoxy)ethanol 
• 5292-43-3 bromoacetic acid tert-butyl ester 

Downstream Products

• 1448451-72-6 tert-butyl 17-azido-3,6,9,12,15-pentaoxaheptadecan-1-oate 

Relevant articles and documents

Protein degradation through covalent inhibitor-based PROTACs

Tremendous advancements in proteolysis targeting chimera (PROTAC) technology have been made in recent years. However, whether a covalent inhibitor-based PROTAC can be developed remains controversial. Here, we successfully developed chimeric degraders based on covalent inhibitors to degrade BTK and BLK kinases, demonstrating that covalent inhibitor-based PROTACs are viable and useful tools.

ANTI-EGFR ANTIBODY DRUG CONJUGATES

The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.

Identification and Characterization of von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1

Proteolysis targeting chimeras (PROTACs) are bifunctional molecules that recruit an E3 ligase to a target protein to facilitate ubiquitination and subsequent degradation of that protein. While the field of targeted degraders is still relatively young, the potential for this modality to become a differentiated and therapeutic reality is strong, such that both academic and pharmaceutical institutions are now entering this interesting area of research. In this article, we describe a broadly applicable process for identifying degrader hits based on the serine/threonine kinase TANK-binding kinase 1 (TBK1) and have generalized the key structural elements associated with degradation activities. Compound 3i is a potent hit (TBK1 DC50 = 12 nM, Dmax = 96%) with excellent selectivity against a related kinase IKK?, which was further used as a chemical tool to assess TBK1 as a target in mutant K-Ras cancer cells.